Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | approved for marketing | — | — | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT04507503 | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | approved for marketing | — | — | Taiho Oncology, Inc.INDUSTRY | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT02065765 | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 5 | Jan 9, 2025 | clinicaltrials |
| NCT02307812 | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Jan 9, 2025 | clinicaltrials |
| NCT00906984 | TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma(TheraSphere) | approved for marketing | — | — | University of California, IrvineOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05345678 | Himalaya Early Access Program | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01076517 | A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma | approved for marketing | — | — | Stanford UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT02436044 | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | approved for marketing | — | — | Ming ZhaoOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00786058 | A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 | approved for marketing | — | — | CONKO-StudiengruppeOTHER | 0 | Jun 15, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials